Although the CRAFITY score consists of two non-expensive and easily obtained blood tests such as CRP and aFP, it is critical to mention that the study was retrospective and the patients who were studied could have received immunotherapy for HCC not only in the 1st line (approximately 40% of cases), but also in later lines, suggesting high heterogeneity of the study group. This evidence concerns the gene CRP and hepatocellular carcinoma.